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TOR (Target of Rapamycin) is a highly conserved protein kinase and a central controller of cell growth. TOR is found in two
functionally and structurally distinct multiprotein complexes termed TOR complex 1 (TORC1) and TOR complex 2 (TORC2). In
the present study, we developed a two-dimensional liquid chromatography tandem mass spectrometry (2D LC-MS/MS) based
proteomic strategy to identify new mammalian TOR (mTOR) binding proteins. We report the identification of Proline-rich Akt
substrate (PRAS40) and the hypothetical protein Q6MZQ0/FLJ14213/CAE45978 as new mTOR binding proteins. PRAS40 binds
mTORC1 via Raptor, and is an mTOR phosphorylation substrate. PRAS40 inhibits mTORC1 autophosphorylation and mTORC1
kinase activity toward eIF-4E binding protein (4E-BP) and PRAS40 itself. HeLa cells in which PRAS40 was knocked down were
protected against induction of apoptosis by TNFa and cycloheximide. Rapamycin failed to mimic the pro-apoptotic effect of
PRAS40, suggesting that PRAS40 mediates apoptosis independently of its inhibitory effect on mTORC1. Q6MZQ0 is structurally
similar to proline rich protein 5 (PRR5) and was therefore named PRR5-Like (PRR5L). PRR5L binds specifically to mTORC2, via
Rictor and/or SIN1. Unlike other mTORC2 members, PRR5L is not required for mTORC2 integrity or kinase activity, but
dissociates from mTORC2 upon knock down of tuberous sclerosis complex 1 (TSC1) and TSC2. Hyperactivation of mTOR by
TSC1/2 knock down enhanced apoptosis whereas PRR5L knock down reduced apoptosis. PRR5L knock down reduced apoptosis
also in mTORC2 deficient cells. The above suggests that mTORC2-dissociated PRR5L may promote apoptosis when mTOR is
hyperactive. Thus, PRAS40 and PRR5L are novel mTOR-associated proteins that control the balance between cell growth and
cell death.
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INTRODUCTION
TOR (Target of Rapamycin) kinase is a highly conserved, central
controller of cell growth [1–3]. The fundamental importance of
TOR is underscored by genetic studies showing TOR to be
essential for cell growth and development; disruption of the TOR
gene is lethal in all examined species [4–12]. In humans,
dysfunctional mTOR signaling plays an important role in many
if not most cancers, as well as in diseases such as tuberous sclerosis
complex (TSC, #191100 OMIM) and lymphangiomyelomatosis
(LAM, #606690 OMIM). TOR is found, from yeast to human, in
two functionally and structurally distinct multiprotein complexes
termed TOR complex 1 (TORC1) and TORC2 [13–15]. The
rapamycin-sensitive mammalian TOR complex 1 (mTORC1)
consists of mTOR, mLST8 and Raptor [13,16,17]. mTORC2
contains Rictor and SIN1 instead of Raptor, and is rapamycin-
insensitive [14,15,18–20]. Knock out of Raptor, SIN1 or Rictor in
mice is embryonic lethal, indicating that both mTORC1 and
mTORC2 are essential [19–22].
mTORC1 is activated by nutrients (amino acids), anabolic
growth factors (e.g., insulin and insulin-like growth factor), and
cellular energy (ATP) [1–3]. The growth factor signal and energy
status are transmitted to mTORC1 via the essential tumor
suppressor tuberous sclerosis complex (TSC) proteins TSC1 and
TSC2 [23,24]. The TSC heterodimer (TSC1-TSC2) is a GTPase
activating protein (GAP) that inhibits the essential small GTPase
Rheb [25,26]. Rheb-GTP binds and activates mTORC1 [27]. Akt
(also known as PKB) phosphorylates and inactivates TSC2 in
response to growth factors [28], whereas AMPK phosphorylates
and activates TSC2 in response to low energy (high AMP) [29,30].
Nutrients impinge on mTORC1 at the level of Rheb or mTORC1
by a poorly understood mechanism involving the type III PI3K
hVps34 [27,31]. The upstream regulators of the more recently
identified mTORC2 are not known, but mTORC2 appears to
respond at least to growth factors, possibly via TSC1-TSC2 [32].
mTORC1 and mTORC2 separately control many cellular
processes that collectively determine cell growth and development.
mTORC1 controls transcription, protein synthesis, ribosome
biogenesis, nutrient transport, and autophagy, among other
processes. mTORC1 controls protein synthesis via phosphoryla-
tion of S6 kinase (S6K) and eIF-4E binding protein (4E-BP), two
key regulators of translation initiation [3,33,34]. mTORC2
controls organization of the actin cytoskeleton via small Rho-type
GTPases and Protein Kinase C [14,15,35], and thereby
determines the shape and possibly motility of the cell. In addition,
mTORC2 phosphorylates Ser473 in the hydrophobic motif of Akt
and thereby activates Akt toward substrates such as the Forkhead
transcription factor FOXO and the apoptosis regulator BAD [19–
21,36].
Academic Editor: Mark Cookson, National Institutes of Health, United States of
America
Received May 23, 2007; Accepted November 3, 2007; Published November 21,
2007
Copyright:  2007 Thedieck et al. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the
original author and source are credited.
Funding: We acknowledge support from the Peter und Traudl Engelhorn Stiftung
zur Fo ¨rderung der Biotechnologie und Gentechnik (KT), the Roche Research
Foundation (PP), and the Swiss National Science Foundation and the Canton of
Basel (MNH). The funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests
exist.
* To whom correspondence should be addressed. E-mail: m.hall@unibas.ch
. These authors contributed equally to this work.
PLoS ONE | www.plosone.org 1 November 2007 | Issue 11 | e1217Although upstream regulators of mTOR, at least for mTORC1,
are relatively well characterized, astonishingly few direct substrates
and downstream effectors of the mTORCs are known. This is
particularly true for mTORC2 which was discovered only recently
and, due to its rapamycin insensitivity, is not pharmacologically
addressable. To identify additional regulators, substrates, and/or
components of the mTORCs, we developed a highly sensitive
mass spectrometry-based screen. Here we report the identification
of two novel mTOR binding proteins, PRAS40 (Q96B36 Swiss-
Prot) and PRR5L (Q6MZQ0 Swiss-Prot), which bind specifically
to mTORC1 and mTORC2, respectively. We further character-
ize the roles of these two proteins in mTOR complex formation
and function.
RESULTS AND DISCUSSION
PRAS40 and PRR5L bind specifically to mTORC1 and
mTORC2
To identify new mTOR binding proteins, we used a ‘gel-less’ mass
spectrometry-based method to screen for mTOR associated
proteins. mTOR complexes, first purified by large scale immuno-
precipitations (IPs) with antibody directed against mTOR, were
digested with trypsin and after detergent removal subjected
directly to two-dimensional liquid chromatography tandem mass
spectrometry (2D LC-MS/MS). Within a single 2D LC-MS/MS
run up to 270 different proteins were identified. To identify
specific mTOR interactors, we compared mTOR and mock IPs,
and chose those proteins that were present only in the mTOR IPs.
Furthermore, to qualify as a specific interactor, a protein had to be
identified in at least three out of four independent mTOR IP
experiments. We reproducibly identified all known members of the
mTOR complexes (Table 1). The sequence coverage for mTOR,
Rictor, mLST8 and Raptor was about 20%, while sequence
coverage for SIN1 was 13.8%. The above experiment was
repeated with antibodies specific for Rictor or Raptor and, as
expected, mTOR and mLST8 were found in both the Rictor and
Raptor IPs, whereas SIN1 was found only in the Rictor IP.
In addition to the known mTORC partners, we also identified
novel mTOR interacting proteins. The proline-rich Akt substrate
PRAS40 (10.6% sequence coverage) was found in mTOR and
Raptor IPs but not in Rictor IPs (Table 1). These interactions were
confirmed by co-IP experiments with HeLa and HEK293 cells
(Figure 1). PRAS40 is therefore a specific mTORC1 binding
partner (Figure 1A). PRAS40 was originally discovered as an Akt
substrate of unknown function [37]. During the preparation of this
manuscript, two studies appeared suggesting that PRAS40 is an
mTORC1 inhibitor [38,39]. In addition to PRAS40, we identified
the hypothetical protein Q6MZQ0/FLJ14213/CAE45978 as
a specific mTORC2 interactor (Table 1). Q6MZQ0 was cloned
with an N-terminal GST tag and its interaction with mTORC2
was confirmed by co-IP and GST pull downs from HeLa and
HEK293 cells (Figure 1B). Since Q6MZQ0 displays 39%
sequence similarity with the proline rich protein PRR5, we
named it PRR5-Like protein (PRR5L). PRR5L is an unchar-
acterized protein. The related protein PRR5, however, is highly
expressed in kidney and has been suggested to be a tumor
suppressor since it is down regulated in a subset of breast tumors
[40].
Earlier studies on the mTORCs failed to detect PRAS40 and
PRR5L possibly because both have an apparent molecular weight
of approximately 40 kDa as measured by SDS-PAGE. Former
searches for mTOR binding proteins relied on IPs followed by
SDS-PAGE analysis. The co-migrating heavy chain of the IP
antibody used in these earlier experiments might have masked
PRAS40 and PRR5L. Our 2D LC-MS/MS approach also
identified Transferrin Receptor 1 (P02786 Swiss-Prot), NICE-4
(Q14157 Swiss-Prot), Plectin 1 (Q6S383 Swiss-Prot), and Thymo-
poietin (P42166 Swiss-Prot) as potential mTOR binding proteins,
but direct co-IP experiments indicated that these were non-specific
binding proteins (data not shown).
PRAS40 binds mTORC1 via Raptor
Following rapamycin treatment, PRAS40 dissociated from mTOR
(Figure 1A). However, released PRAS40 remained bound to
Raptor which, as reported previously [41], is also released from
mTOR upon rapamycin treatment. Furthermore, PRAS40
binding to mTOR was strongly reduced when Raptor was
knocked down (Figure 2A). These findings indicate that PRAS40
binds mTORC1 via Raptor. We also observed that PRAS40
associated less well with a kinase dead version of mTOR
(Figure 2B), suggesting that mTORC1-mediated phosphorylation
of PRAS40 (see below) may affect the PRAS40- mTORC1
interaction. Our findings are in agreement with recent PRAS40
studies showing that PRAS40 binds preferentially to Raptor [38],
and that the mTOR kinase domain is also involved in PRAS40
binding [39].
Table 1. mTORC1 and mTORC2 associated proteins identified by 2D-LC-MS/MS
..................................................................................................................................................
Protein
# Identifications
(out of 4 independent IPs) Sequence Coverage Identified in IP of Predicted MW (Da) Length (aa)
mTOR Rictor Raptor
mTOR 4 26.2% x x x 288892 2549
Rictor 4 21% x x 192217 1708
Raptor 4 18.2% x x 149038 1335
SIN1 4 13.8% x x 59123 522
PRR5L 3 5.2% x x 40866 368
mLST8 4 21.5% x x x 35902 326
PRAS40 3 10.6% x x 27383 256
mTOR complexes were purified by immunoprecipitation (IP) with antibody directed against mTOR, Rictor or Raptor. Immunoprecipitates were analyzed by 2D LC-MS/
MS. Proteins that were found in at least three out of four mTOR IPs, but not in mock IPs, were considered specific. IPs with antibodies directed against Rictor or Raptor
indicated whether a candidate was specific for mTORC1 or mTORC2, respectively.
doi:10.1371/journal.pone.0001217.t001
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PLoS ONE | www.plosone.org 2 November 2007 | Issue 11 | e1217PRAS40 is a substrate and an inhibitor of mTORC1 in
vitro
The above results suggested that PRAS40 is phosphorylated by
mTORC1. To investigate if PRAS40 is an mTORC1 substrate, we
performed in vitro kinase assays with mTORC1 or mTORC2 and
purified PRAS40. PRAS40 was phosphorylated weakly by both
mTORC1 and mTORC2. Importantly, we also found that PRAS40
inhibited mTORC1 autophosphorylation but not mTORC2 autop-
hosphorylation (Figure 3A), suggesting that the weak phosphorylation
of PRAS40 by mTORC1 might be due to PRAS40-mediated
inhibition of mTORC1. To investigate whether PRAS40 inhibits
mTORC1 kinase activity, we performed in vitro kinase assays with the
known mTORC1 substrate 4E-BP and increasing concentrations of
purified PRAS40. PRAS40 inhibited both mTORC1 autopho-
sphorylation and mTORC1 phosphorylation of 4E-BP, in a concen-
tration dependent manner (Figure 3B). In addition, PRAS40
phosphorylation inversely correlated with the concentration of
PRAS40 in the kinase reaction, suggesting that PRAS40 is indeed
both a substrate and an inhibitor of mTORC1 kinase activity. Our
finding that PRAS40 inhibits mTORC1 kinase activity toward 4E-BP
and PRAS40 is in agreement with the observation of Sancak et al.
[38] and Vander Haar et al. [39] that PRAS40 inhibits mTORC1
toward S6K1. Hence, we conclude that PRAS40 is a broad
mTORC1 inhibitor that inhibits mTORC1 kinase activity toward
itself, 4E-BP, S6K1, and PRAS40. It remains to be determined
whether mTORC1-mediated phosphorylation of PRAS40 plays
a role in PRAS40’s ability to bind and inhibit mTORC1.
Interestingly, we found that phosphorylation of the Akt consensus
site T246 in PRAS40 is moderately reduced in Rictor knock down
cells(data notshown).ThissuggeststhatmTORC2mayactivateAkt
toward PRAS40. This in turn suggests that mTORC2, via PRAS40,
may be upstream of mTORC1. If mTORC2 is indeed upstream of
mTORC1, it might be only under specific conditions or only with
regard to particular mTORC1 substrates (other than S6K1), as we
andothersfailedtodetectaneffectofmTORC2disruptiononS6K1
phosphorylation [14,15]. The potential regulation of mTORC1 by
mTORC2 requires further investigation.
PRAS40 deficiency prevents induction of apoptosis
by TNFa and cycloheximide
Constitutively active mTOR reduces apoptosis [42] whereas
inhibition of mTORC1 with rapamycin induces or facilitates
apoptosis in several cell lines [43–48]. We therefore reasoned that
the mTORC1 inhibitor PRAS40 might promote apoptosis and
that PRAS40 knock down would thus protect cells against the
induction of apoptosis. To investigate this possibility, we examined
the effect of PRAS40 knock down on the sensitivity of HeLa cells
to apoptosis induction by TNFa in combination with cyclohex-
imide. To monitor apoptosis, treated cells were processed for
visualization of DNA and cleaved PARP. We found that apoptosis
was reduced in PRAS40 knock down cells (Figure 4A), suggesting
that PRAS40 is indeed pro-apoptotic. To analyze if PRAS40
promotes apoptosis via its inhibitory effect on mTORC1, we
investigated if rapamycin suppressed the effect of a PRAS40
deficiency on TNFa/cycloheximide induced apoptosis in HeLa
cells. Rapamycin failed to prevent the reduction in apoptosis
caused by PRAS40 knock down (Figure 4B). In addition,
rapamycin treatment did not affect apoptosis induction by
TNFa/cycloheximide in control cells (Figure 4B), even after 6h
of rapamycin treatment (data not shown). The finding that
rapamycin failed to mimic the pro-apoptotic effect of PRAS40,
suggests that PRAS40 mediates apoptosis independently of its
Figure 1. Confirmation of PRAS40 and PRR5L binding to mTOR. A. PRAS40 is associated specifically with mTORC1. mTOR, Rictor, Raptor and mock
IPs were performed with HeLa and HEK293 extracts and analyzed by immunoblotting. PRAS40 was found specifically in mTOR and Raptor IPs. 1 h
rapamycin treatment of cells dissociated a Raptor-PRAS40 subcomplex from mTOR. B. PRR5L is associated specifically with mTORC2. HeLa or
HEK293 cells were transfected with GST-PRR5L or the empty plasmid. mTOR, Rictor, Raptor and mock IPs and GST pull downs were analyzed by
immunoblotting. GST-PRR5L is detected specifically in mTOR and Rictor IPs. mTOR, Rictor and SIN1, but not Raptor, are detected specifically in GST-
PRR5L pull downs.
doi:10.1371/journal.pone.0001217.g001
PRAS40 and PRR5L Bind mTOR
PLoS ONE | www.plosone.org 3 November 2007 | Issue 11 | e1217inhibitory effect on mTORC1. However, PRAS40 T246 phos-
phorylation (PRAS40-pT246) appears to protect neuronal cells
from apoptosis after stroke [49]. PRAS40-pT246 has also been
proposed to promote cell survival in cancer cells [50]. The fact that
T246 is the site via which Akt negatively regulates PRAS40’s
ability to inhibit mTORC1 [38] suggests that PRAS40 may indeed
be pro-apoptotic via its ability to inhibit mTORC1. To explain the
apparent discrepancy with our inability to induce apoptosis with
rapamycin, PRAS40 may have to inhibit both mTORC1 and
a second, unknown rapamycin insensitive target (or only this
second target) to perform its pro-apoptotic function. mTORC1
may be the more important target in those cell lines where
rapamycin induces or facilitates apoptosis [43–48].
PRR5L binds mTORC2 via Rictor/SIN1
Since we initially identified endogenous PRR5L as an mTORC2
binding protein in HeLa cells, we verified PRR5L expression in
HEK293 cells by RT-PCR (Figure 5A). PRR5L is strongly
expressed in both HeLa and HEK293 cells. Subsequent experi-
ments were performed with HEK293 cells due to the higher
transfection efficiency with these cells. To investigate whether
PRR5L binds directly to mTOR or via other mTORC2 members,
we examined PRR5L binding to mTOR in SIN1 knock down
cells. As reported previously [18,19], we observed a reduction in
the amount of Rictor when SIN1 was knocked down (Figure 5B),
supporting the earlier suggestion that these two proteins stabilize
each other. We found that the amount of mTOR in GST-PRR5L
pull downs from the SIN1/Rictor deficient cells was substantially
reduced compared to control cells (Figure 5B). This suggests that
PRR5L binds to mTOR via Rictor and/or SIN1. To investigate
whether PRR5L is required for mTORC2 integrity, we examined
the binding of mTOR and SIN1 to Rictor in cells knocked down for
PRR5L (Figure 5C). The amount of mTOR and SIN1 bound to
Rictor, as measured by co-IP, remained unchanged in PRR5L
knock down cells. We then investigated if PRR5L is required for
mTORC2 kinase activity. Phosphorylation of Akt S473 and Paxillin
Y118 is reduced upon mTORC2 disruption [14,15]. However, in
PRR5L deficient cells the levels of Akt-pS473 and Paxillin-pY118
remained unchanged (Figure 5D). The findings that PRRL5 is not
required for mTORC2 integrity or for phosphorylation of known
mTORC2 targets suggest that PRR5L is not an mTORC2
upstream regulator or an integral component of mTORC2.
PRR5L is phosphorylated by mTOR in vitro
To determine whether PRR5L is a phosphorylation substrate for
mTOR, we performed in vitro kinase assays with mTORC1 or
mTORC2 and purified PRR5L. We found that PRR5L is
phosphorylated by both mTORC1 and mTORC2, the former
but not the latter phosphorylation being sensitive to rapamycin
treatment (Figure 3A). Hence, PRR5L might be regulated through
mTOR phosphorylation. PRR5L addition did not affect
mTORC1 or mTORC2 autophosphorylation (Figure 3A), sug-
gesting that PRR5L does not function as an mTORC2 inhibitor
like PRAS40 for mTORC1. The significance of the phosphory-
lation of PRR5L by mTOR, in particular by mTORC1, remains
to be determined. The above results taken together suggest that
PRR5L is a downstream effector of mTORC2.
PRR5L dissociates from mTORC2 in TSC1/2 deficient
cells
To investigate whether TSC1-TSC2 influences PRR5L binding to
mTORC2, we examined GST-PRR5L pull downs from TSC1/2
deficient cells. TSC1/2 deficient cells exhibited reduced amounts
of Rictor and mTOR bound to GST-PRR5L (Figure 6A). The
above finding suggests that PRR5L dissociates from mTORC2 in
cells with hyperactive mTOR signaling. It remains to be
determined whether the effect of TSC1/2 knock down on PRR5L
binding is via mTORC1 or mTORC2. TSC1/2 knock down
hyperactivates mTORC1 [1–3] and possibly also mTORC2
(K.D.M and M.N.H., unpublished).
PRR5L promotes apoptosis
Hyperactive mTOR signaling, in TSC knock out MEFs, enhances
induction of apoptosis by FCS starvation or TNFa/cycloheximide
[51,52]. In agreement, we found that TSC1/2 knock down in
human cells, in which PRR5L dissociates from mTORC2, also
Figure 2. PRAS40 interacts with mTORC1. A. PRAS40 binds mTOR via
Raptor. HEK293 cells were transfected with Raptor or control siRNA
vectors and incubated for 4 days, followed by mTOR IP and
immunoblotting. mTOR IPs and cell extracts were probed with
antibodies directed against the indicated proteins. Since knock down
of Raptor reduced the cellular amount of PRAS40, the PRAS40 signal in
the IPs was quantified relative to PRAS40 levels in the corresponding
extract. Quantitations were averaged over three independent experi-
ments. Raptor knock down reduced the amount of PRAS40 associated
with mTOR by 50%, as compared to control cells. B. mTOR kinase
domain is involved in PRAS40 binding. HEK293 cells were transfected
with a plasmid expressing wild type (WT) HA-mTOR or kinase dead (KD)
HA-mTOR or an empty control plasmid, and incubated for 48 h followed
by extract preparation and IP with an anti-HA antibody. PRAS40 levels
in the extracts remained unaltered. PRAS40 association with mTORC1
containing HA-mTOR KD was moderately reduced as compared with
mTORC1 containing HA-mTOR WT.
doi:10.1371/journal.pone.0001217.g002
PRAS40 and PRR5L Bind mTOR
PLoS ONE | www.plosone.org 4 November 2007 | Issue 11 | e1217enhances TNFa/cycloheximide induced apoptosis (Figure 6B). To
investigate whether PRR5L plays a role in apoptosis, we examined
if PRR5L knock down affects TNFa/cycloheximide induced
apoptosis. PRR5L knock down cells were less apoptotic compared
to control cells, at various time points after TNFa/cycloheximide
treatment, suggesting that PRR5L is pro-apoptotic (Figure 4A and
S1). The finding that PRR5L is pro-apoptotic is consistent with the
suggested role of the related protein PRR5 as tumor suppressor
[40]. Furthermore, the observation that PRR5L is pro-apoptotic
and is released from mTORC2 in cells with enhanced apoptosis
(TSC1/2 deficient cells) suggests that released PRR5L may
promote apoptosis. This in turn suggests that PRR5L is
downstream of mTORC2 in mediating apoptosis. To test this
possibility, we investigated whether a PRR5L deficiency still
reduces apoptosis in cells knocked down for TORC2. We found
that cells knocked down for both PRR5L and the mTORC2
component SIN1 were similar to cells knocked down only for
PRR5L, with regard to induction of apoptosis by TNFa/
cycloheximide (Figure 4C). This observation is consistent with
a model in which PRR5L acts downstream of mTORC2. In
particular, in response to hyperactive mTOR signaling, PRR5L
may dissociate from mTORC2 to promote apoptosis. However,
our data do not rule out the possibility that PRR5L controls
apoptosis independently of mTORC2. It is important to note that
mTORC2 also promotes cell survival via a mechanism other than
tethering PRR5L. mTORC2 phosphorylates and activates Akt
which then phosphorylates and inactivates the pro-apoptotic
factors BAD and FOXO1/3a [19,20,36]. The above taken
together suggests that either too much or too little mTOR
signaling predisposes a cell to apoptosis. There seems to be
a delicate balance between cell growth and cell death that may be
mediated at least in part by PRR5L.
In summary, we describe two new mTOR interactors, PRAS40
and PRR5L. PRAS40 binds specifically to mTORC1 whereas
PRR5L is mTORC2 specific. PRAS40 binding to mTORC1 is
primarily via Raptor but also requires mTOR kinase activity.
mTORC1 phosphorylates PRAS40 and this phosphorylation may
contribute to the mTORC1-PRAS40 interaction. Furthermore,
PRAS40 inhibits mTORC1 autophosphorylation and mTORC1
kinase activity toward its substrates 4E-BP and PRAS40. This
observation extends two recent studies showing that PRAS40
inhibits mTORC1 toward its substrate S6K [38,39]. Thus,
PRAS40 is an upstream negative regulator of mTORC1. We
also show that PRAS40 is pro-apoptotic, but this may be an
mTORC1 independent function of PRAS40. PRR5L, the new
mTORC2-specific interactor, binds mTOR via SIN1 and/or
Rictor. Unlike Rictor and SIN1, PRR5L is not required for
mTORC2 integrity or mTORC2 kinase activity toward its
downstream readouts Akt and Paxillin. Furthermore, we observed
that PRR5L binding to mTORC2 is reduced in TSC1/2 deficient
cells. We conclude that PRR5L dissociates from mTORC2 in cells
with hyperactive mTOR signaling. We show that a TSC1/2
deficiency enhances TNFa/cycloheximide induced apoptosis.
Conversely, knock down of PRR5L prevents apoptosis, even in
mTORC2 deficient cells. We suggest that PRR5L is downstream
of mTORC2 and is pro-apoptotic. It will be of interest to
determine whether PRR5L is a tumor suppressor as suggested for
the related protein PRR5 [40].
Figure 3. mTOR phosphorylates PRAS40 and PRR5L, and PRAS40 inhibits mTOR kinase activity. A. mTOR phosphorylates PRAS40 and PRR5L.
Kinase assays were performed using mTORC1 or mTORC2 immunopurified from HEK293 cells, and purified PRAS40, GST-PRR5L (PRR5L) or 4E-BP as
substrates. Rapamycin (100 nM) and purified FKBP12 were added directly to the reaction. Both PRR5L and PRAS40 are phosphorylated in vitro by both
mTORCs. Phosphorylation by mTORC1 was rapamycin-sensitive. B. PRAS40 inhibits mTORC1 kinase activity toward 4E-BP and PRAS40 itself. Kinase
assays were performed using mTORC1 immunopurified from HEK293 cells, purified 4E-BP as a substrate, and increasing concentrations of PRAS40.
PRAS40 inhibits mTORC1 autophosphorylation and mTORC1 phosphorylation of 4E-BP and PRAS40, in a concentration-dependent manner.
doi:10.1371/journal.pone.0001217.g003
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PLoS ONE | www.plosone.org 5 November 2007 | Issue 11 | e1217Figure 4. PRAS40 and PRR5L are pro-apoptotic. A. PRR5L and PRAS40 knock down cells are resistant to TNFa/cycloheximide induced apoptosis.
HeLa cells were transfected with PRR5L, PRAS40 or control siRNA and incubated for 48 h, followed by 2 h induction of apoptosis with TNFa and
cycloheximide. Cells were fixed and stained with DAPI and cleaved PARP antibody, and the percentage of apoptotic cells was quantified. B. PRAS40’s
effect on apoptosis is independent of mTORC1. HeLa cells were transfected with PRAS40 or control siRNA and incubated for 48 h, and treated with
100 nM rapamycin or carrier for 1 h before incubation with TNFa and cycloheximide for 2 h to induce apoptosis. Extracts were analyzed by
immunoblotting with the indicated antibodies. C. PRR5L deficiency protects against apoptosis in SIN1 deficient cells. HeLa cells were transfected
with diced PRR5L siRNA and/or synthetic siRNA against SIN1 as indicated, or the appropriate control siRNAs. Cells were incubated for 48 h, and
apoptosis was induced with TNFa and cycloheximide for 2 h. Cells were fixed and stained with DAPI and cleaved PARP antibody, and the percentage
of apoptotic cells was quantified. The efficiency of SIN1 knock down was assessed in parallel by immunoblotting (right panel).
doi:10.1371/journal.pone.0001217.g004
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Screen for mTOR binding proteins and mass
spectrometry
mTOR binding proteins were purified essentially as reported [14].
For each IP experiment, 6 10 cm dishes of HeLa cells at 70%
confluence were used. IPs were performed with 6 mgo fm T O R
(Santa Cruz), Rictor or Raptor (Bethyl), or control goat (Santa Cruz)
or rabbit (Bethyl) antibodies. Antibodies were bound to 300 mL
magnetic Protein G coupled Dynabeads (Invitrogen). Digestion was
performed on the beads [53] with 1 mg of Trypsin (Promega). After
drying, detergents were removed by hydrophilic interaction
chromatography on PolyHYDROXYETHYL TopTips (PolyLC
Inc.) according to the manufacturer’s instructions. Ammonium
acetate remainders were removed by repeated drying of the samples.
LC-MS/MS
The peptides were analyzed by two-dimensional capillary liquid
chromatography and tandem MS using a PolySULFOETHYL A
ion-exchange column (0.15650 mm, PolyLC, Columbia, MD),
connected in series to a C18 trap column (Zorbax 300SB,
0.3650 mm, Agilent Technologies, Basel, Switzerland), and to
a Magic C18 separation column (0.16100 mm, Thermo Scientific,
Basel, Switzerland). The peptides were injected first onto the cation
exchange column. Unadsorbed peptides were trapped on the
Zorbax column and eluted onto the separation column with a linear
75 min gradient from 2 to 75% B (0.1% acetic acid in 80%
acetonitrile) in solvent A (0.1% acetic acid in 2% acetonitrile). Next,
peptides that had been retained by the ion-exchange column were
sequentially eluted and trapped on the C18 trap column with 10 mL
pulses of 50, 100, 150, 200, 250, 300, 350, 400, and 500 mM
ammonium acetate, pH 3.3. Peptides eluted by each individual salt
pulse were separated by the acetonitrile gradient as described above.
The flow was delivered with a Rheos 2200 HPLC system (Thermo
Scientific, Basel, Switzerland) at 50 mL/min. A precolumn splitter
reduced the flow to approximately 500 nl/min. The eluting peptides
were ionized by a Finnigan nanospray ionization source (Thermo
Scientific, Basel, Switzerland). The LTQ orbitrap instrument was
operated in the data-dependent mode. A survey scan was performed
in the Orbitrap between m/z 400-1600 Da at 60,000 resolution. The
three most abundant ions detected were fragmented in the LTQ
mass spectrometer and mass analyzed in the Orbitrap at a resolution
of 7,500. Singly charged ions were not subjected to fragmentation.
The normalized collision energy was set to 35%. Individual MS/MS
spectra were searched against the NCBI non-redundant databank
using the TurboSequest software [54]. The Sequest filter parameters
were as follows: Xcorr versus charge state was 1.50 for singly, 2.00
for doubly, and 2.50 for triply charged ions, respectively; the DCN
was 0.1, and the protein probability was set to 0.01.
Figure 5. PRR5L binds to mTORC2 via SIN1 and/or Rictor but does not
affect mTORC2 integrity or kinase activity. A. PRR5L expression in
HeLa and HEK293 cells, and PRR5L knock down efficiency. Top panel:
Total RNA was purified from HeLa or HEK293 cells, followed by reverse
transcription and PCR with primers corresponding to PRR5L. As
a negative control, reverse transcription without the transcriptase
enzyme was performed. Endogenous PRR5L is expressed in both cell
lines. Bottom panel: HEK293 cells were cotransfected with a GST-PRR5L
vector and PRR5L siRNA or control siRNA, and incubated for 48 h.
Immunoblots were performed on with antibody against GST or Actin. B.
PRR5L binds mTOR via SIN1 and/or Rictor. HEK293 cells were
cotransfected with a GST-PRR5L vector and a SIN1 siRNA vector or
a control siRNA vectors, and incubated for 4 days. GST pull downs were
immunoblotted with the indicated antibodies. GST-PRR5L was detected
with an anti-GST antibody. mTOR binding to GST-PRR5L is weaker in the
absence of SIN1 and Rictor. C. mTORC2 remains intact in PRR5L knock
down cells. HEK293 cells were transfected with PRR5L siRNA or control
siRNA and incubated for 48 h. Rictor IPs were immunoblotted with the
indicated antibodies. D. mTORC2 readouts are unaltered in PRR5L
knock down cells. HEK293 cells were transfected with PRR5L siRNA or
control siRNA and incubated for 48 h. Immunoblots were performed on
protein extracts with the indicated antibodies. The phosphorylation of
Akt S473 and paxillin Y118 is unaltered by PRR5L knock down.
doi:10.1371/journal.pone.0001217.g005
Figure 6. Analysis of TSC1/2 knock down cells. A. PRR5L is released
from mTORC2 in TSC1/2 deficient cells. TSC knock down was induced
in TSCsi293 cells by tetracycline treatment for 4 days. Cells were
cotransfected with GST-PRR5L vector and incubated for 2 days,
followed by GST pull downs and immunoblots with the indicated
antibodies. GST-PRR5L was detected with an anti-GST antibody. B.
TSC1/2 knock down facilitates apoptosis. TSCsi293 and T-REx-293
(control) cells were treated with tetracycline for 4 days. Apoptosis was
induced by 1.5 h treatment with TNFa and cycloheximide. Extracts were
probed with the indicated antibodies.
doi:10.1371/journal.pone.0001217.g006
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Rictor, Raptor and SIN1 siRNA constructs were previously
described [14,20]. An empty pSuper-GFP-neo construct was used
as a control. HA-mTOR and kinase dead HA-mTOR constructs
were a kind gift from Dr. G. Thomas and were described
previously [29], the control empty vector was created by cutting
out the mTOR fragment using NotI and PstI.
The coding region of PRR5L was cloned from human cDNA
made from HeLa cells, using the following primers: 59 ATG ACC
CGC GGC TTC G 39 (forward, contained also restriction sites for
either BamHI or SpeI), and 59 T CAG CTG AGG GAA GCA
CAG 39 (reverse, contained also a NotI restriction site). The PCR
product was digested either with BamHI and NotI or with SpeI
and NotI, and cloned into pGEX-6P-1 or pEBG, respectively.
Recombinant GST-PRR5L was expressed from pGEX-6P-1 and
purified from E. coli.
The generation of the inducible TSC knock down cell line
TSCsi293 from an HEK293 cell line (T-REx-293, Invitrogen),
that expresses the tetracycline repressor protein TetR, and its
handling were as described (K. D. M. and M. N. H., submitted).
Cycloheximide was dissolved in water and used at a final
concentration of 2.5 mg/mL (Calbiochem), rapamycin was
dissolved in DMSO and used at a final concentration of
100 nM (LC laboratories), TNFa was dissolved in PBS containing
0.1% BSA, and used at a final concentration of 10 ng/mL (R&D
systems). Purified PRAS40 was from Biosource, purified 4E-BP
was from Stratagene.
RNA interference
siRNAs against PRAS40 and PRR5L and control siRNA against
Luciferase were generated as described [55] using the following
reagents: 56 Megascript T7 Kit (Ambion); Turbo Dicer siRNA
Generation Kit (Genlantis); RNA Purification System (Invitrogen).
Primers for PRAS40 were as follows: gene specific primers:
forward: ttgcctccacgacatcgcac, reverse: tatttccgcttcagcttctgg, T7
primers: forward: gcgtaatacgactcactataggccacagggctgccactg, re-
verse: gcgtaatacgactcactataggaagtcgctggtgttaagcc. Primers for
PRR5L were as follows: gene specific primers: forward:
tcgtccattgtccagatgttg, reverse: agctgagggaagcacagttc, T7 primers:
forward: gcgtaatacgactcactataggctcatcctgcagagtgttc, reverse:
gcgtaatacgactcactataggagctccgagccctcctg. For SIN1 knock down,
a synthetic pool siRNA or the appropriate control pool siRNA
(Dharmacon) were used as described [19].
Cell culture and transfections
HEK293 and HeLa cells were maintained in DMEM containing
10% fetal bovine serum. Small RNAi was transfected with
INTERFERin (Polyplus transfection). For combined transfection
of small RNAi and DNA, jetSI-ENDO (Polyplus transfection) was
used. DNA was transfected using either lipofectamin (Invitrogen)
or jetPEI (Polyplus transfection). All transfections were done
according to the manufacturers’ instructions, for 48 h for
expression or small RNAi, or for 4 days in the case of pSuper-
based siRNA. Cells were harvested with lysis buffer that contained
40mM HEPES pH 7.5, 120 mM NaCl, 1 mM EDTA, 0.3%
CHAPS, supplemented with protease inhibitor cocktail (Roche).
In the cases where phosphorylation was to be detected, the lysis
buffer was also supplemented with10 mM NaF, 10 mM NaN3,
10 mM p-nitrophenylphosphate, 10 mM sodium pyrophosphate,
and 10 mM beta-glycerophosphate. Lysates were incubated for
20 minutes on ice, then cleared by a spin at 600 g for 3 minutes.
Supernatants were collected and used for immunoprecipitations,
GST pull downs or immunoblots.
RT-PCR
RNA was purified using the RNAeasy mini kit (Qiagen), according
to the manufacturer’s instructions. One microgram of total RNA
was reverse transcribed using Superscript II reverse transcriptase
(Invitrogen) and random nonamers (Sigma). The reverse tran-
scription reaction was used as a template for PCR, with the
PRR5L primers described above.
Immunoblotting
Protein extracts were prepared as described [14], resolved on
SDS-PAGE and transferred to PVDF membranes (Immobilon-P,
Millipore). Immunoblots were performed using the following
antibodies: Rictor, Raptor (Bethyl); mTOR (Santa Cruz); S6K,
phospho-S6K, Akt, phospho-Akt (Thr308), phospho-Akt (Ser473),
PARP, cleaved PARP (Cell signaling); PRAS40 (Biosource;
PRAS40 antibodies were previously described [37]); SIN1 (kind
gift from Dr. Bing Su, University of Yale, CT). GST-PRR5L was
detected with a GST antibody (GE Healthcare), since no antibody
for PRR5L was available.
Apoptosis assay
RNAi experiments were performed by transfecting HeLa cells for
48 hours in a 96-well format. 48 hours after siRNA transfection,
apoptosis was induced for the indicated times as described [56].
Apoptosis, in response to TNFa and cycloheximide treatment, was
quantified by a cleaved PARP (cPARP) immunofluorescence assay
(Cell Signaling). The assay was performed according to the
manufacturer’s instructions. Briefly, after apoptosis induction, cells
were fixed with pre-chilled 100% methanol for 5min and then
washed with 0.1% Triton X-100 and PBS sequentially. Cells were
thenincubated withanti-cPARPantibody(1/200dilution)overnight
at 4uC, washed and incubated for 1 hour with a mixed solution
containingAlexa568 goat anti-Rabbit antibody(1/500 dilution)and
Hoechst (Invitrogen, 1/1000 dilution). Images were automatically
taken by an ImageXpress Micro (Molecular Devices, Sunnyvale,
USA). Apoptosis was quantified by automated image processing.
The multi-wavelength cell scoring application module of the analysis
software MetaXpress was used to quantify, at the single cell level, the
intensity of cPARP staining (200 was used as the intensity above
background for cPARP images). More than 6000 cells per condition
were analyzed. For analysis by immunoblotting cPARP levels were
detected by human or mouse specific antibodies (Cell Signaling).
mTORC1 was inhibited by preincubation with 100 nM rapamycin
for 1 h, and apoptosis was subsequently induced by TNFa/
cycloheximide for 1.5 h in the presence of rapamycin.
Immunoprecipitation and GST pull down
Immunoprecipitations were performed as described [14]. Pull
downs of GST-PRR5L were similar to immunoprecipitations,
with glutathione-coupled beads (GE Healthcare).
Kinase assay
Kinase assays were performed as described [14].
SUPPORTING INFORMATION
Figure S1 Time course for apoptosis induction. HeLa cells were
transfected with PRR5L or control siRNA and incubated for 48 h,
followed by apoptosis induction for the indicated time spans by
TNFalpha and cycloheximide. Cells were fixed and stained with
cleaved PARP antibody, and the percent of apoptotic cells was
quantified.
Found at: doi:10.1371/journal.pone.0001217.s001 (0.64 MB TIF)
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